Skip to main content
. 2014 Jul 22;9(7):e101320. doi: 10.1371/journal.pone.0101320

Table 1. Characteristics of included studies.

Study source Participants Mean difference in sitting versus standing posture (95% CI)
Aghamir et al, 2005, Iran N = 20, stratified: Group A:
Group A: n = 10 healthy men Qmax 0.50 (−1.55 to 2.55)
Group B: n = 10 LUTS/BPH patients TQ −2.50 (−4.79 to 0.21)
PVR n/a
Group B:
Qmax 0.20 (−0.92 to 1.32)
TQ −6.50 (−20.33 to 7.33)
PVR −63.00 (−96.58 to −29.42)
Amjadi et al, 2011, Iran N = 31 healthy men Qmax 1.00 (−2.17 to 4.17)
TQ −1.80 (−5.65 to 2.05)
Choudhury et al, 2010, India N = 61 healthy men Qmax −4.00 (−5.90 to −2.10)
TQ 9.30 (4.84 to 13.76)
PVR 1.50 (0.04 to 2.96)
El-Bahnasawy et al, 2008, Egypt N = 200 LUTS/BPH patients Qmax 0.70 (−0.37 to 1.77)
TQ −2.50 (−7.22 to 2.22)
PVR −13.10 (−24.00 to −2.20)
Eryıldırım et al, 2008, Turkey N = 30 healthy men Qmax 4.50 (2.04 to 6,96)
TQ −1.40 (−3.04 to 0.24)
PVR −0.20 (−3.35 to 2.95)
Koc et al, 2006, Turkey N = 110 LUTS/BPH patients, stratified: Both groups:
Group A: N = 44 (alpha blockers) Qmax 1.80 (0.76 to 2.84)
Group B: N = 66 (control group) TQ −2.50 (−7.31 to 2.31)
PVR −3.40 (−18.71 to 11.91)
Norg et al, 2009, Netherlands N = 20 LUTS/BPH patients Qmax −0.55 (−1.08 to −0.02)
TQ −0.38 (−1.48 to 0.72)
Salem et al, 2009, Egypt N = 100 LUTS/BPH patients Both groups:
Qmax 5.90 (5.12 to 6.68)
PVR −55.70 (−70.47 to −40.93)
Ünsal et al, 2004, Turkey N = 88, stratified: Group A:
Group A: N = 44 (healthy men) Qmax 0.50 (−1.04 to 2.04)
Group B: N = 44 (LUTS/BPH patients) PVR −1.20 (−3.38 to 0.98)
Group B:
Qmax −0.70 (−1.72 to 0.32)
PVR 3.30 (−19.80 to 26.40)
Ünsal et al, 2004, Turkey N = 36 healthy men Qmax 0.71 (−0.64 to 2.06)
PVR 0.60 (−1.33 to 2.53)
Yamanishi et al, 1999, Japan N = 21 healthy men Qmax −2.10 (−5.77 to 1.57)

Table 1 Characteristics of included studies for the difference between the urodynamic parameters: maximum urinary flow rate (ml/s, Qmax), voiding time (s, TQ), and post-void residual volume (ml, PVR) in the sitting versus standing position in healthy males and male patients with Lower Urinary Tract Symptoms (LUTS).